Modicus Prime

Modicus Prime develops enterprise software it calls an AI Management System (AIMS), positioned alongside established regulated-industry systems such as QMS (quality), MES (manufacturing) and LIMS (laboratories), but scoped to the AI lifecycle. The platform centralizes AI inventory, validation evidence, datasets and model versions, approvals, risk assessments, technical change history, decision records, traceability and lifecycle performance monitoring, and it is designed to integrate with a customer's existing quality management system and data science tooling so that internal and vendor-supplied AI models can be governed in one place.

The company frames the problem as regulators including the FDA and EMA issuing observations and warning letters relating to inappropriate AI usage, combined with uncontrolled enterprise AI adoption, difficulty qualifying third-party AI suppliers within their intended context of use, unmanaged model change control and retraining drift, and decentralized audit evidence. Alongside the core software, Modicus Prime offers optional validated AI-in-GxP applications such as computer vision for quality control and language models for deviation assistance, hands-on AI validation workshops and audit-readiness support, and industry engagement work including co-authorship of frameworks and publications.

Press coverage of the company's 2026 financing describes the product as a Trustworthy AI Compliance Software that acts as a central compliance layer bridging data science, IT, quality and compliance functions, providing a single source of truth for regulators across sites and geographies. It is described as supporting biologics, cell and gene therapy, and vaccine manufacturing environments, and as serving pharmaceutical companies, CROs, CMOs and CDMOs.

Business model

Modicus Prime sells enterprise compliance software to regulated pharmaceutical organizations, complemented by education services (AI validation workshops and audit-readiness support) and industry collaboration programs. Prospects are onboarded through a structured 30-day trial in which a single AI system or AI supplier is added to the platform, a context of use is defined, data and model validation are connected, and audit-ready records and reports are generated.

Revenue is generated from enterprise software for AI audit readiness, sold to pharmaceutical companies and CDMOs and initiated via a trial, together with education offerings such as on-site AI validation workshops and audit-readiness support.

Traction

Financing announcements in May 2026 followed multiple rollouts of the company's compliance software across global pharmaceutical companies, CROs, CMOs, CDMOs and adjacent regulated sectors, and the company describes itself as venture-backed with international pharmaceutical customers. Its website states it is trusted by top 50 pharma companies.

Latest developments

In May 2026 the company announced an additional $4.5M in funding led by Frist Cressey Ventures, with backing from Silverton Partners and Oncology Ventures, bringing total funding to $8M. The capital is earmarked for expanded customer support for international pharmaceutical customers and continued platform enhancement to support customer deployments and AI compliance needs.